

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

NIPPON SHINYAKU CO., LTD.,	)	
Plaintiff,	)	
	)	C.A. No. 21-1015 (GBW)
v.	)	<b>DEMAND FOR JURY TRIAL</b>
	)	
SAREPTA THERAPEUTICS, INC.,	)	
Defendant.	)	
<hr/>		
SAREPTA THERAPEUTICS, INC. and THE	)	
UNIVERSITY OF WESTERN AUSTRALIA,	)	
Defendant/Counter-Plaintiffs,	)	
	)	
v.	)	
	)	
NIPPON SHINYAKU CO., LTD. and NS	)	
PHARMA, INC.,	)	
Plaintiff/Counter Defendants.	)	

**[PROPOSED] ORDER**

AND NOW, this \_\_\_\_ day of \_\_\_\_\_, 2024 it is hereby ordered that:

1. Plaintiff Nippon Shinyaku Co., Ltd.'s and Counter-Defendant NS Pharma, Inc.'s Motion for Summary Judgment regarding Infringement of Certain NS Patents is GRANTED;
2. Judgment is entered in favor of Plaintiff and against defendant Sarepta Therapeutics, Inc. finding that (i) Sarepta Therapeutics, Inc. directly and indirectly infringes claims 1-3 of US Patent No. 10,385,092 (the “092 Patent”), claims 1-2 of US Patent No. 10,407,461 (the “461 Patent”), and claims 1-2 of US Patent No. 10,487,106 (the “106 Patent”) under 35 U.S.C. § 271 (a), (b), and (c); and (ii) Sarepta Therapeutics, Inc. indirectly infringes claims 1-12 of US Patent No. 10,647,741 (the “741 Patent”) and claims 1-4 of US Patent No. 10,662,217 (the “217 Patent”) under 35 U.S.C. § 271 (b) and (c).

---

Honorable Gregory B. Williams